Related Experiment Video
Updated: Jun 18, 2026
Functional Neuroimaging Using Ultrasonic Blood-brain Barrier Disruption and Manganese-enhanced MRI
Published on: July 12, 2012
Manganese-enhanced MRI of hypoxic-ischemic brain injuries using Mn-DPDP
1Medical Imaging Center of the First Affiliated Hospital, School of Medicine of Xi'an Jiaotong University Xi'an, Shannxi Province, China. yj1118@mail.xjtu.edu.cn
Abstract:
In this study, Mn-dipyridoxaldiphosphate (MnDPDP), a clinically approved manganese contrast agent for hepatic and pancreatic imaging, was demonstrated for the first time for manganese-enhanced MRI (MEMRI) in brains of normal young rats (n = 4) and rats with hypoxic-ischemic (H-I) insult at postnatal day 7 (n = 8). After a single intraperitoneal injection of low dosage with 0.1micromol/g in postnatal 14 days, 2D T1-weighted image (T1WIs), T1 maps, T2-weighted images (T2WIs) and T2 maps were acquired at 7 Tesla 1 day before, 1 day and 7 days after MnDPDP injection. The image contrast changes induced by MnDPDP appeared as the hyperintensity in T1WIs and the hypointensity in T2WIs. T1 and T2 values decreased in the regions of Mn enhancement. Such enhancement presented as a delayed pattern that was more pronounced in 7 day after MnDPDP injection, suggesting the sustained Mn accumulation due to MnDPDP. Moreover, the MnDPDP enhancement in H-I brains was more pronounced in the lesion sites and was easily detectable in T1WI, T1 map, T2WI and T2 map. The results demonstrated here support the possibility of using MnDPDP as a 'slow release' Mn(2+) for clinical diagnosis of various neuropathologies.
Insights
Mn-dipyridoxaldiphosphate (MnDPDP) shows promise for manganese-enhanced MRI (MEMRI) in rat brains. This contrast agent effectively highlights brain lesions in hypoxic-ischemic injury models.
Area of Science:
- Neuroimaging
- Biomedical Engineering
- Radiology
Background:
- Mn-dipyridoxaldiphosphate (MnDPDP) is an established manganese contrast agent for liver and pancreas imaging.
- Manganese-enhanced MRI (MEMRI) utilizes manganese ions to enhance image contrast.
Purpose of the Study:
- To evaluate MnDPDP for MEMRI in the brains of normal and hypoxic-ischemic (H-I) injured young rats.
- To assess the potential of MnDPDP as a slow-release manganese (Mn2+) agent for neuropathology diagnosis.
Main Methods:
- Single intraperitoneal injection of MnDPDP (0.1 micromol/g) in postnatal day 14 rats.
- Acquisition of 2D T1-weighted images (T1WIs), T1 maps, T2-weighted images (T2WIs), and T2 maps at 7 Tesla.
- Imaging performed 1 day before, and 1 and 7 days after MnDPDP injection.
Main Results:
- MnDPDP induced hyperintensity in T1WIs and hypointensity in T2WIs, with decreased T1 and T2 values.
- Delayed and sustained Mn enhancement was observed, more pronounced 7 days post-injection.
- Enhanced MnDPDP signal was significantly more pronounced in H-I brain lesion sites.
Conclusions:
- MnDPDP demonstrates potential as a slow-releasing Mn2+ agent for brain imaging.
- The agent effectively highlights neuropathological changes, particularly in H-I injury models.
- MnDPDP shows promise for clinical diagnosis of various brain conditions using MEMRI.
